Grizzly Bulls
Financial research concept

Life Sciences Tools Specialty Diagnostics Organic Revenue Growth

measures acquisition- and currency-adjusted revenue growth in a specialty diagnostics segment.

By Lee BaileyPublished Oct 1, 2026
Research context

See what supports this page, how current it is, and where comparable or historical context is available.

Research date
Oct 1, 2026Use the dated article and cited sources for the definition, examples, and stated limitations.
Operating-model context
10 connected conceptsPart of the reviewed Life Sciences Tools & Biopharma Services Economics; issuer definitions remain distinct where disclosed.
Company examples
1 reviewed companyRelationships reflect supported examples, not a normalized cross-company KPI ranking.
  1. Healthcare and immunodiagnostics led the increase
  2. Specialty Diagnostics is broader than diagnostic laboratory volume
  3. Part of the Life Sciences Tools & Biopharma Services Economics
  4. See It in Company Research
  5. Continue Research

Life sciences tools Specialty Diagnostics organic revenue growth measures segment revenue growth after excluding acquisition, divestiture, and currency effects under Thermo Fisher Scientific's non-GAAP methodology.

Thermo Fisher reported 5% organic revenue growth in Specialty Diagnostics for the second quarter of 2026. Revenue increased to $1.205B from $1.134B.

Healthcare and immunodiagnostics led the increase

Thermo Fisher said growth in the healthcare market channel and immunodiagnostics business primarily drove the organic increase.

Reported revenue grew 6%, including a 1% currency contribution and no acquisition or divestiture contribution.

Specialty Diagnostics is broader than diagnostic laboratory volume

The segment includes specialty diagnostic businesses and market channels, so its organic rate is not interchangeable with laboratory requisition growth or revenue per requisition.

Use it with Specialty Diagnostics segment income margin and Analytical Instruments organic revenue growth.

Primary source: Thermo Fisher Scientific Q2 2026 Form 10-Q.

Part of the Life Sciences Tools & Biopharma Services Economics

Connects Thermo Fisher's four operating segments through issuer-defined organic revenue growth, segment-income conversion, and disclosed business-level contributions to reported growth.

Browse the full operating model in Company Analysis →
Where this concept fits

See It in Company Research

These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.

Continue Research

Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.

Compare stocks

Compare specialty diagnostics organic growth

Compare specialty-diagnostics organic growth without substituting diagnostic-lab requisition or patient-volume measures.

Continue research

Explore more topics in the Financial Research Encyclopedia.